SLC5A2 and type 2 diabetes mellitus: <b>Background:</b> Sodium-glucose cotransporter 2 inhibitors (SGLT2 inhibitors), initially developed for glycemic control in type 2 diabetes, have demonstrated robust cardiovascular and renal benefits.